Immunocompetent C57/B6 mice implanted subcutaneously with the syngeneic MC38 cells were treated with atezolizumab, durvalumab, or a positive control anti-PD-L1 mouse antibody (clone 10F.9G2), and the tumor size was monitored for 25 days following the start of the treatment (Figure 5C). The gene discussed is CD274; the disease is neoplasm.